Frazier Life Sciences Management’s Avidity Biosciences RNAM Stock Holding History

Frazier Life Sciences Management’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-983,125	Closed	-$70.9M	–	42
2025 Q4	$70.9M	Buy	983,125 +358,125	+57%	+$23.1M	1.9%	14
2025 Q3	$27.2M	Hold	625,000	–	–	0.82%	27
2025 Q2	$17.8M	Buy	625,000 +100,000	+19%	+$2.98M	0.71%	30
2025 Q1	$15.5M	Buy	+525,000	New	+$16.4M	0.71%	28
2023 Q2	–	Sell	-500,000	Closed	-$7.67M	–	50
2023 Q1	$7.67M	Hold	500,000	–	–	0.56%	35
2022 Q4	$11.1M	Buy	+500,000	New	+$7.46M	0.69%	29

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

Frazier Life Sciences Management's RNAM Position: Q1 2026 in Review

Frazier Life Sciences Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 983,125 shares — an estimated $70.9M sold.

Frazier Life Sciences Management first reported a position in RNAM in Q4 2022 and held it in 6 quarters. The position peaked at $70.9M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Frazier Life Sciences Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Frazier Life Sciences Management sold 983,125 Avidity Biosciences shares in Q1 2026, an estimated $70.9M.
Frazier Life Sciences Management first reported a position in Avidity Biosciences in Q4 2022 and held it in 6 quarters.
Frazier Life Sciences Management's Avidity Biosciences position peaked at $70.9M in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Frazier Life Sciences Management's 13F filing for Q1 2026, filed 15 May 2026.